Niraparib is an orally active small molecule PARP inhibitor developed by Tesaro to treat ovarian cancer.

Function:
Niraparib is an orally active small molecule PARP inhibitor developed by Tesaro to treat ovarian cancer.
The drug is approved by the US FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.